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While the exact number of individuals with sickle 
cell disease (SCD) in the United States is not known, it is 
estimated that SCD affects 90,000–100,000 Americans and 
occurs among 1 out of every 500 African-American births 
and among 1 out of every 36,000 Hispanic-American births. 
Improvements in therapy reduced mortality rates by up to 68 
percent, particularly among young patients with SCD 0–3 
years of age.1 However, the average life expectancy is estimated 
to be 53–60 years of age. Thus, further improvements in 
therapy are required to reduce morbidity and mortality and 
increase the life expectancy for these patients.2 What role does 
red blood cell (RBC) transfusion play in the care of patients 
with SCD and are transfusion medicine specialists doing all 
they can to minimize the complications of transfusion?
RBC transfusion plays a major role in the management 
of many of the acute and chronic complications of SCD, 
including anemia, acute chest syndrome, stroke, and pain 
crisis.3 Transfusion complications can include iron overload, 
infectious disease transmission, and volume overload. Some 
complications, such as alloimmunization and hyperviscosity, 
may be found more frequently in patients with SCD than in 
the general population. Alloimmunization results in delays 
in obtaining compatible blood and in increased incidence 
of delayed hemolytic transfusion reactions.3 A 10-year 
retrospective review reported alloimmunization rates as high 
as 29 percent in transfused pediatric patients with SCD and 47 
percent in transfused adult patients with SCD when partial or 
extended RBC antigen matching was not performed.4 The use 
of antigen-matching protocols can reduce, but not eliminate, 
the risk of antibody formation.5,6
The National Institutes of Health (NIH) recommends that 
a RBC phenotype (ABO, Rh, Kell, Duffy, Kidd, Lewis, Lutheran, 
P, and MNS at a minimum) be obtained on all patients with 
SCD older than 6 months. In addition, patients should be 
transfused with leukocyte-reduced, “antigen matched” RBCs 
or RBCs matched for C, E, and K to limit development of 
antibodies.2 These recommendations, developed by those who 
care for patients with SCD, are not universally followed when 
transfusing these patients. The Centers for Disease Control 
and Prevention (CDC) notes that while SCD is a “major public 
health concern,” individuals with SCD have less access to 
comprehensive medical care than patients with other genetic 
disorders, such as cystic fibrosis.1 Laboratories tend to vary in 
the transfusion protocols they follow when treating patients 
with SCD. A survey from the College of American Pathologists 
(CAP) found that only 37 percent of laboratories perform a 
RBC phenotype on nonalloimmunized patients with SCD and 
only 75 percent of these laboratories select phenotype-matched 
(most commonly for C, E, and K) units when transfusing.7
In 2006, the editors of Immunohematology invited 
authors from several comprehensive sickle cell centers to 
describe their donor recruitment and transfusion management 
protocols.8–12 As Shulman noted in his introduction, it was 
interesting to review these articles for their discussions on 
the use of phenotype-matched donor blood for transfusion, 
given the lack of consensus on this issue, and on subsequent 
alloimmunization.13 The majority of programs reported 
providing CEK phenotype-matched blood.4,5 One program 
provided CEK phenotype-matched blood only after a patient 
developed his or her first RBC antibody. The extent of 
antigen matching for alloimmunized patients varied among 
the programs. Of interest, only one program described the 
use of molecular methods to predict the phenotype of either 
the patient or the donor.12 Data on the frequency of RBC 
alloimmunization were usually not provided, although one 
program reported a rate of approximately 5 percent.9  
I am pleased to welcome four authors from 200614–17 and 
three new authors18–20 to this issue of Immunohematology. 
The authors were asked to focus on a description of their 
transfusion management protocol rather than their donor 
recruitment protocol. Information requested included the 
use of phenotype- or genotype-matched blood in routine 
and emergency transfusion situations; donor RBC selection 
including age of transfused blood, cytomegalovirus (CMV) 
seronegative vs leukocyte reduced, irradiated, and hemoglobin 
S tested; and outcome data, including allo- and auto-antibody 
formation, cost, or clinical benefit. It is interesting to read the 
articles and particularly note the role that molecular testing is 
playing in the transfusion management of patients with SCD. 
Transfusion medicine specialists can play an important role in 
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extending these practices from the comprehensive sickle cell 
centers into the community.
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